Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer
The Prostate ( IF 2.8 ) Pub Date : 2021-08-26 , DOI: 10.1002/pros.24215 Zhipeng Wang 1 , Sha Zhu 1 , Jinge Zhao 1 , Ling Nie 2 , Xueqin Chen 2 , Mengni Zhang 2 , Ni Chen 2 , Guangxi Sun 1 , Junru Chen 1 , Yuchao Ni 1 , Jindong Dai 1 , Zhenhua Liu 1 , Ronggui Tao 1 , Xingming Zhang 1 , Xudong Zhu 1 , Haoran Zhang 1 , Jiayu Liang 1 , Zilin Wang 1 , Ben He 1, 3 , Pengfei Shen 1 , Hao Zeng 1
The Prostate ( IF 2.8 ) Pub Date : 2021-08-26 , DOI: 10.1002/pros.24215 Zhipeng Wang 1 , Sha Zhu 1 , Jinge Zhao 1 , Ling Nie 2 , Xueqin Chen 2 , Mengni Zhang 2 , Ni Chen 2 , Guangxi Sun 1 , Junru Chen 1 , Yuchao Ni 1 , Jindong Dai 1 , Zhenhua Liu 1 , Ronggui Tao 1 , Xingming Zhang 1 , Xudong Zhu 1 , Haoran Zhang 1 , Jiayu Liang 1 , Zilin Wang 1 , Ben He 1, 3 , Pengfei Shen 1 , Hao Zeng 1
Affiliation
To explore whether metastatic castration-resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC-P) subtypes respond differently to abiraterone and docetaxel treatment.
中文翻译：
前列腺导管内癌的异质性与转移性去势抵抗性前列腺癌患者标准一线治疗的不同疗效相关
探讨具有不同前列腺导管内癌 (IDC-P) 亚型的转移性去势抵抗性前列腺癌 (mCRPC) 患者对阿比特龙和多西他赛治疗的反应是否不同。
更新日期：2021-09-23
中文翻译：
前列腺导管内癌的异质性与转移性去势抵抗性前列腺癌患者标准一线治疗的不同疗效相关
探讨具有不同前列腺导管内癌 (IDC-P) 亚型的转移性去势抵抗性前列腺癌 (mCRPC) 患者对阿比特龙和多西他赛治疗的反应是否不同。
京公网安备 11010802027423号